This review provides a perspective on the clinical benefit of such targeted therapies in advanced thyroid cancer to date, with a focus on the present clinical management of RET-driven advanced thyroid cancer in Europe and the landscape of prospective advancements. The gene discussed is RET; the disease is thyroid gland carcinoma.